title: Single-dose etoposide in combination with vincristine and doxorubicin in the treatment of small-cell lung cancer (SCLC).
abstract: From July 1980, 104 consecutive patients with previously untreated small-cell lung cancer (SCLC) received vincristine 1.4 mg/m2, doxorubicin (Adriamycin) 40 mg/m2, and Etoposide (VePesid) 300 mg/m2 intravenously (as a single infusion) every 3 weeks. The overall response rate (complete response plus partial response) was 58%. In 47 patients with limited disease the response rate was 66% with 21/47 (45%) complete responders. Treatment was delivered on an outpatient basis. Toxicity was mild, and in 455 rapid infusions of etoposide, there have been no adverse reactions.
authors.forename: A R
authors.initials: AR
authors.lastname: Timothy
authors.forename: F M
authors.initials: FM
authors.lastname: Calman
authors.forename: N T
authors.initials: NT
authors.lastname: Bateman
authors.forename: M
authors.initials: M
authors.lastname: Farebrother
authors.forename: M L
authors.initials: ML
authors.lastname: Slevin
authors.forename: D
authors.initials: D
authors.lastname: Bellamy
authors.forename: R D
authors.initials: RD
authors.lastname: Rubens
authors.forename: J
authors.initials: J
authors.lastname: Costello
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D011034:Podophyllotoxin